HOSPIRA UK LIMITED

1. Financial Health Score: B (Stable but Inactive)

Explanation: HOSPIRA UK LIMITED receives a grade of B, not due to operational vigor, but because it exhibits perfect "corporate health" for a dormant entity. The company shows zero signs of financial distress, carries no visible liabilities, and benefits from the immense systemic support of its parent, Pfizer. However, because the business has no active commercial metabolism (trading activity), it cannot score higher; it is in a state of controlled, intentional suspended animation.

2. Key Vital Signs

• Pulse (Trading Activity): Flatline. The company is officially categorized as "Dormant" by Companies House. It has no significant financial transactions flowing through its veins. This is not a symptom of decline, but a strategic cessation of operations.
• Blood Pressure (Financial Liabilities): Healthy/Low. As a dormant entity, it carries no current or long-term trading debts on its public record. Its financial obligations are limited to basic administrative maintenance.
• Genetic Makeup (Ownership & Control): Robust. The People with Significant Control (PSC) are Pfizer Limited and Pfizer Pfe Uk Limited, both owning more than 75% of shares and voting rights. The company has the ultimate "corporate immune system" backing it through its parent entity.
• Medical History (Corporate Lineage): Complex M&A History. Previous names (Hillmast, F.H. Faulding, Mayne Pharma, and Hospira) reveal a long history of acquisitions and rebrandings typical in the global pharmaceutical sector, culminating in its absorption into the Pfizer group.
• Vital Organs (Directors): Functional. The board includes international representation (American and British directors), which is standard for a subsidiary of a global pharmaceutical corporation, acting essentially as the trustees of the dormant entity.

3. Diagnosis: Corporate Suspended Animation

Based on the financial data, HOSPIRA UK LIMITED is not suffering from any commercial illness; rather, it is in a state of corporate suspended animation.

Following Pfizer's global acquisition of Hospira in 2015, the UK entity—originally established to manufacture and wholesale pharmaceutical products (SIC codes 21100, 21200, 46460)—was gradually wound down. The "Dormant" status indicates that the company has ceased its primary metabolic functions (trading, manufacturing, and wholesaling). It exists on the register strictly as a legal shell. This is a highly common, healthy practice in the pharmaceutical industry where parent companies retain dormant subsidiaries for regulatory holding, intellectual property management, or historical legal continuity. The patient is alive, but only on life support, sustained entirely by the Pfizer parent company.

4. Recommendations: Maintaining Wellness

While the company is not in distress, maintaining a dormant entity still requires routine "hygiene" to prevent complications:

• Routine Check-ups (Compliance Maintenance): Continue to file Dormant Accounts and Confirmation Statements on time. Even though the company is inactive, failure to file annual returns can lead to regulatory infections (penalties) or eventual dissolution by the Registrar.
• Review Necessity (Strategic Assessment): Pfizer's corporate governance team should periodically evaluate whether HOSPIRA UK LIMITED still serves a strategic purpose (e.g., holding a specific license or trademark). If the entity is no longer needed, a voluntary strike-off (corporate euthanasia) would save on administrative costs.
• Protect Against Identity Fraud (Corporate Hygiene): Dormant companies with strong parentage are sometimes targeted for corporate hijacking or fraud. Ensure that the registered office and director details are secure, and monitor the Companies House register for any unauthorized filings.